Email Alert | RSS

Journal of Tuberculosis and Lung Disease ›› 2023, Vol. 4 ›› Issue (2): 169-177.doi: 10.19983/j.issn.2096-8493.20230018

• Review Articles • Previous Articles     Next Articles

Research advance of biological target therapy and its cause of anaphylaxis for common allergic diseases

Ru Yi, Li Lisha(), Guan Kai()   

  1. Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Translational Medical Center, Beijing 100730, China
  • Received:2023-01-10 Online:2023-04-20 Published:2023-04-07
  • Contact: Li Lisha,;Guan Kai,
  • Supported by:
    National Natural Science Foundation of China(82070033)


With the understanding of pathogenesis, biologics are gradually being applied as a mean of precision medicine for a variety of common allergic diseases, and good therapeutic results have been achieved. However, compared to foreign countries, China has fewer approved drugs and patients’ treatment options are more limited, so expanding the range of drugs and indications is the way forward. As with any emerging drug, safety remains a key issue for biologics, where anaphylaxis, a rapid-onset, life-threatening and serious adverse reaction, have been found to occur in the treatment of a variety of biologics, but it is not well understood or taken seriously enough. The authors therefore review eight biologics used internationally to treat common allergic reactions: omalizumab (anti-IgE), mepolizumab (anti-IL-5), reslizumab (anti-IL-5), benralizumab (anti-IL-5), dupilumab (anti-IL-4, IL-13), tralokinumab (anti-IL-13), nemolizumab (anti-IL-31R) and tesepelumab (anti-TSLP), and summarises the incidence of anaphylaxis to these biologics in order to promote awareness among healthcare professionals, to provide reasonable and necessary supervision after drug administration, and to be able to identify and manage anaphylaxis when they occur.

Key words: Anaphylaxis, Drug hypersensitivity, Biotargeted therapy

CLC Number: